Bonraybio Co. Ltd.

As of June 30, 2026, Bonraybio Co. Ltd. carries a market capitalization of 2.46B, placing it among publicly traded companies globally. Its enterprise value stands at 1.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Bonraybio Co. Ltd. has 24.80M shares outstanding.

As of June 30, 2026, Bonraybio Co. Ltd. trades at a trailing price-to-earnings ratio of 24.07. The price-to-sales ratio is 7.82, and the price-to-book ratio stands at 3.75.

As of June 30, 2026, Bonraybio Co. Ltd. trades at an EV/EBITDA multiple of 16.16 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.81 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.32 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Bonraybio Co. Ltd. trades at an EV/FCF ratio of 29.72, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.93B versus a market cap of 2.46B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bonraybio Co. Ltd. maintains a current ratio of 9.98, meaning it holds 10.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.80, indicating moderate leverage, while an interest coverage ratio of 1,075.39 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Bonraybio Co. Ltd. posted a return on equity (ROE) of 17.39, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 15.32 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 15.91, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 17.21, useful for judging operating efficiency across full business cycles. The company generates approximately 4.15M in revenue per employee across its workforce of 80.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.74 indicates how many times Bonraybio Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Bonraybio Co. Ltd. recorded 9.31M in income tax expense. That works out to an effective tax rate of 7.94, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 117.29M, leaving 107.98M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Bonraybio Co. Ltd.'s stock has declined approximately 32.57% over the past 52 weeks. The 50-day moving average sits at 97.39, while the 200-day moving average is 116.62.

Over the twelve months ended June 30, 2026, Bonraybio Co. Ltd. generated 332.21M in revenue and converted that into 107.98M in net income, yielding earnings per share of 4.10. EBITDA reached 119.37M, while operating income came in at 105.33M.

As of June 30, 2026, Bonraybio Co. Ltd. holds 535.64M in cash and equivalents against 5.26M in total debt, resulting in a net debt position of -196.64M. Total book value stands at 656.72M, with working capital of 575.79M providing operational flexibility.

Bonraybio Co. Ltd. produced 96.71M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -31.88M in capital expenditures, free cash flow totaled 64.83M - equivalent to 2.47 per share.

Over the twelve months ended June 30, 2026, Bonraybio Co. Ltd. posted a gross margin of 77.37, reflecting its pricing power and cost economics. The operating margin of 31.70 and net profit margin of 32.50 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Bonraybio Co. Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 2.48, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.65, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bonraybio Co. Ltd. shareholders.

Bonraybio Co. Ltd.'s most recent stock split took place on August 26, 2026 with a 40:49 split ratio.

As of June 30, 2026, Bonraybio Co. Ltd. has an Altman Z-Score of 24.43, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.